Skip to content

Built For Patients

Guided By Biology.

OUR PHILOSOPHY

At Jabez, we Are developing a smarter model for cancer therapy.

At the core of Jabez’s strategy is a therapeutic framework we call 3-C Therapeutics – cancer treatments that are:

Convenient

Orally available, low-toxicity, outpatient-compatible to maximize compliance.

Cost-Effective

Scalable synthesis, efficient manufacturing, global potential

Cooperative (Synergistic)

Rationally synergistic with standard-of-care treatments

We Are Experts In Drug Development

Jabez was founded by a team with deep experience in drug development, clinical strategy, and translational biology.

Tamara Jovonovich, PhD

CEO & President

Rob Lewis

Chief Operating Officer

Clinical Partners:

OUR STRATEGIC VISION

Jabez Is More Than A Small Molecule Company

Our strategy balances short-term clinical progress with a long-term asset acquisition and development engine grounded in the 3-C model.

Advance Our Lead Program

Establish safety, expand to synergistic indications (e.g., AML, MM), and demonstrate proof-of-concept for the Jabez model.

Demonstrate 3-C Clinical Impact

We aim to show that 3-C therapeutics can drive real-world outcomes—improving efficacy without added toxicity or logistical burden.

Expand Our Portfolio

We will identify and license additional assets that fit our 3-C filter to build a pipeline of smart, synergistic therapeutics.

Scale the Jabez Model

With each successful program, we expand our ability to systematically evaluate, acquire, and deploy high-impact therapies.

CLINICAL DEVELOPMENT

Our Clinical Trials

Jabez Biosciences is proud to be a clinical-stage biotechnology company. We are currently enrolling patients in a Phase 1 clinical trial evaluating our lead candidate in advanced solid tumors and non-Hodgkin lymphoma.

Latest

News & Events